 |
|
Reduced Ocular Allergy With Fixed-Combination 0.2% Brimonidine–0.5% Timolol
Jorge A. Alvarado, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
We read with great interest the article by Sherwood and colleagues1 describing the 12-month trial of twice-daily fixed-combination 0.2% brimonidine–0.5% timolol vs monotherapy with the individual components. The authors observed that the rate of allergic conjunctivitis in patients who received the combination product (5.2%) was significantly lower than that seen in patients who received brimonidine alone (9.4%). The authors acknowledge that a partial explanation for the improved tolerability may be related to the fact that the combination product is dosed twice daily while brimonidine was dosed 3 times daily. We would like to postulate that the lower rate of ocular allergy observed in their study may be a direct result of the addition of timolol to brimonidine based on a concept originally described by us a decade ago.2
This concept of ours is based on 2 observations describing the fundamental effect of adrenergic agonists/antagonists on cell . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED LETTER
Reduced Ocular Allergy With Fixed-Combination 0.2% Brimonidine–0.5% Timolol—Reply
Mark B. Sherwood, E. Randy Craven, Connie Chou, Harvey B. DuBiner, Amy L. Batoosingh, Rhett M. Schiffman, and Scott M. Whitcup
Arch Ophthalmol. 2007;125(5):717-718.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Twice-Daily 0.2% Brimonidine–0.5% Timolol Fixed-Combination Therapy vs Monotherapy With Timolol or Brimonidine in Patients With Glaucoma or Ocular Hypertension: A 12-Month Randomized Trial
Mark B. Sherwood, E. Randy Craven, Connie Chou, Harvey B. DuBiner, Amy L. Batoosingh, Rhett M. Schiffman, Scott M. Whitcup, and for the Combigan Study Groups I and II
Arch Ophthalmol. 2006;124(9):1230-1238.
ABSTRACT
| FULL TEXT
|
